DongKook Pharmaceutical Co., Ltd. (KOSDAQ:086450)
South Korea
· Delayed Price · Currency is KRW 15,120
+510 (3.49%)
Apr 1, 2025, 3:30 PM KST
DongKook Pharmaceutical Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Operating Revenue | 812,166 | 730,994 | 661,647 | 594,193 | 559,103 | Upgrade
|
| Other Revenue | - | - | -0 | - | - | Upgrade
|
| Revenue | 812,166 | 730,994 | 661,647 | 594,193 | 559,103 | Upgrade
|
| Revenue Growth (YoY) | 11.10% | 10.48% | 11.35% | 6.28% | 15.93% | Upgrade
|
| Cost of Revenue | 364,598 | 320,443 | 281,999 | 244,272 | 221,983 | Upgrade
|
| Gross Profit | 447,568 | 410,551 | 379,648 | 349,921 | 337,120 | Upgrade
|
| Selling, General & Admin | 328,148 | 310,542 | 277,684 | 257,570 | 227,646 | Upgrade
|
| Research & Development | 30,325 | 25,456 | 21,818 | 24,691 | 18,859 | Upgrade
|
| Other Operating Expenses | 1,343 | 1,278 | 1,350 | 887.7 | 732.4 | Upgrade
|
| Operating Expenses | 367,703 | 343,677 | 306,107 | 286,702 | 254,518 | Upgrade
|
| Operating Income | 79,865 | 66,873 | 73,541 | 63,219 | 82,602 | Upgrade
|
| Interest Expense | -4,497 | -5,868 | -4,320 | -2,883 | -1,796 | Upgrade
|
| Interest & Investment Income | 6,335 | 5,258 | 2,903 | 2,454 | 2,709 | Upgrade
|
| Earnings From Equity Investments | 2,553 | -896.71 | 1,122 | 1,031 | 451.62 | Upgrade
|
| Currency Exchange Gain (Loss) | 1,840 | -65.38 | 708.54 | 2,657 | -2,980 | Upgrade
|
| Other Non Operating Income (Expenses) | -6,790 | 596.82 | -603.97 | 932.71 | -2,834 | Upgrade
|
| EBT Excluding Unusual Items | 79,305 | 65,898 | 73,350 | 67,411 | 78,152 | Upgrade
|
| Gain (Loss) on Sale of Investments | 3,284 | -5,814 | -5,337 | 1,376 | 1,881 | Upgrade
|
| Gain (Loss) on Sale of Assets | 2,148 | 752.89 | 618.82 | 966.3 | -2.32 | Upgrade
|
| Pretax Income | 84,738 | 60,838 | 68,632 | 69,754 | 80,031 | Upgrade
|
| Income Tax Expense | 22,401 | 11,966 | 13,876 | 16,837 | 22,150 | Upgrade
|
| Earnings From Continuing Operations | 62,336 | 48,871 | 54,757 | 52,916 | 57,880 | Upgrade
|
| Minority Interest in Earnings | -1,117 | -1,696 | -1,861 | -2,571 | -1,955 | Upgrade
|
| Net Income | 61,219 | 47,175 | 52,896 | 50,345 | 55,925 | Upgrade
|
| Preferred Dividends & Other Adjustments | 449.93 | 399.85 | - | - | - | Upgrade
|
| Net Income to Common | 60,769 | 46,775 | 52,896 | 50,345 | 55,925 | Upgrade
|
| Net Income Growth | 29.77% | -10.81% | 5.07% | -9.98% | -0.69% | Upgrade
|
| Shares Outstanding (Basic) | 44 | 44 | 44 | 44 | 44 | Upgrade
|
| Shares Outstanding (Diluted) | 45 | 45 | 45 | 45 | 45 | Upgrade
|
| Shares Change (YoY) | 0.01% | 0.02% | 0.01% | - | - | Upgrade
|
| EPS (Basic) | 1382.16 | 1064.03 | 1203.46 | 1145.56 | 1272.52 | Upgrade
|
| EPS (Diluted) | 1368.41 | 1054.64 | 1183.00 | 1126.00 | 1251.00 | Upgrade
|
| EPS Growth | 29.75% | -10.85% | 5.06% | -9.99% | -0.64% | Upgrade
|
| Free Cash Flow | 48,800 | 7,616 | -7,005 | -6,352 | 19,502 | Upgrade
|
| Free Cash Flow Per Share | 1090.81 | 170.27 | -156.64 | -142.04 | 436.09 | Upgrade
|
| Dividend Per Share | 200.000 | - | - | - | - | Upgrade
|
| Gross Margin | 55.11% | 56.16% | 57.38% | 58.89% | 60.30% | Upgrade
|
| Operating Margin | 9.83% | 9.15% | 11.12% | 10.64% | 14.77% | Upgrade
|
| Profit Margin | 7.48% | 6.40% | 7.99% | 8.47% | 10.00% | Upgrade
|
| Free Cash Flow Margin | 6.01% | 1.04% | -1.06% | -1.07% | 3.49% | Upgrade
|
| EBITDA | 108,327 | 87,971 | 92,728 | 80,577 | 97,714 | Upgrade
|
| EBITDA Margin | 13.34% | 12.03% | 14.02% | 13.56% | 17.48% | Upgrade
|
| D&A For EBITDA | 28,462 | 21,098 | 19,187 | 17,358 | 15,112 | Upgrade
|
| EBIT | 79,865 | 66,873 | 73,541 | 63,219 | 82,602 | Upgrade
|
| EBIT Margin | 9.83% | 9.15% | 11.12% | 10.64% | 14.77% | Upgrade
|
| Effective Tax Rate | 26.44% | 19.67% | 20.22% | 24.14% | 27.68% | Upgrade
|
| Advertising Expenses | 83,743 | 76,804 | 66,472 | 67,064 | 58,171 | Upgrade
|
Updated Mar 13, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.